atezolizumab + capecitabine + oxaliplatin

Atezolizumab + capecitabine + oxaliplatin is a combination regimen used primarily in the treatment of gastric and gastroesophageal junction cancers. Atezolizumab is a monoclonal antibody that targets programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and B7.1 receptors, thereby enhancing T-cell mediated immune responses against tumor cells. Capecitabine is an oral prodrug of fluorouracil, an antimetabolite that interferes with DNA synthesis in rapidly dividing cells. Oxaliplatin is a platinum-based chemotherapeutic agent that induces DNA crosslinking and damage, leading to apoptosis in cancer cells. This combination leverages both immunotherapy and cytotoxic chemotherapy to improve outcomes in patients with resectable or advanced gastric or gastroesophageal junction adenocarcinoma[2][3][4].

Other names

XELOX